Clinical Evidence and Cost-Effectiveness: Advanced Cellular Tissue Products for Diabetic Foot Ulcers
Summary: This article provides a comprehensive review of the clinical evidence and cost-effectiveness of advanced cellular/tissue products (CTPs) for diabetic foot ulcers (DFUs), focusing on FDA-approved options like Apligraf and Dermagraft. It demonstrates their superiority over standard care in achieving higher healing rates, shorter closure times, and reduced complications such as infections and amputations, while delivering significant long-term cost savings despite initial expenses. The discussion underscores the urgent need for early intervention in DFU management amid rising diabetes prevalence.
Key Highlights:
- CTPs like Apligraf (human skin equivalent) and Dermagraft (dermal skin substitute) promote faster wound closure and lower amputation risks in chronic DFUs unresponsive to standard care.
- Randomized trials show up to twice the healing rates with CTPs, supported by real-world data and meta-analyses confirming reduced hospitalization and infection risks.
- Economic analyses reveal per-patient savings of $5,253–$6,991 over 18 months, offsetting upfront costs through fewer emergency visits and inpatient stays.
- Challenges include high DFU recurrence (50% within 1 year) and the need for prompt adjunctive therapies to prevent 1 in 6 cases from leading to amputation.
Keywords:
diabetic foot ulcers,
cellular tissue products,
Apligraf,
Dermagraft,
cost-effective wound care